Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIDEC: Subcutaneous Immunoglobulin in De-novo CIDP
2024-515898-96-01Phase 4Completed
- Sponsor
- Central Denmark Region
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of polyvalent human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Central Denmark Region. Primary endpoints: Change in Overall Disability Sum score (ODSS) from baseline to end of phase I (26 weeks) and Change in Overall Disability Sum score (ODSS) during phase II until lowest effective dose reached (up to 60 weeks). Started Oct 2024; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-515898-96-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515898-96-01.